Gianna Kroening
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Gianna Kroening has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Fa-Chyi Lee
Division of Hematology/Oncology, Department of Medicine, University of California Irvine. Irvine, CA
1 shared publication - Farshid Dayyani
University of California Irvine 3 Division of Hematology/Oncology, Department of Medicine Orange, California
1 shared publication - Jason A. Zell
School of Medicine, Chao Family Comprehensive Cancer Center, University of California
1 shared publication - Jennifer B. Valerin
School of Medicine, University of California Irvine, Irvine, CA, USA; Division of Hematology/Oncology, Department of Medicine, University of California Irvine, Orange, CA, USA; Chao Family Comprehensive Cancer Center, University of California, Irvine, CA, USA
1 shared publication - May Cho
Department of Medicine, Division of Hematology and Oncology, University of California Irvine, Irvine, CA 92868, USA
1 shared publication - Naomie Devico Marciano
Department of Medicine, University of California, Irvine, Ca 92868, USA
1 shared publication
Latest Publications
- Open Access
BRCA-Mutated Pancreatic Cancer: From Discovery to Novel Treatment Paradigms
The discovery of BRCA1 and BRCA2 in the 1990s revolutionized the way we research and treat breast, ovarian, and pancreatic cancers. In the case of pancreatic cancers, germline mutations occur in about 10–20% of patients, with mutations in BRCA1 and BRCA2 being the most common. BRCA genes are critical in DNA repair pathways, particularly in homologous recombination, which has a serious impact on genomic stability and can contribute to cancerous cell proliferation. However, BRCA1 also plays a fundamental role in cell cycle checkpoint control, ubiquitination, control of gene expression, and chromatin remodeling, while BRCA2 also plays a role in transcription and immune system response. Therefore, mutations in these genes lead to multiple defects in cells that may be utilized when treating cancer. BRCA mutations seem to confer a prognostic benefit with an improved overall survival due to differing underlying biology. These mutations also appear to be a predictive marker, with patients showing increased sensitivity to certain treatments, such as platinum chemotherapy and PARP inhibitors. Olaparib is currently indicated for maintenance therapy in metastatic PDAC after induction with platinum-based chemotherapy. Resistance has been found to these therapies, and with a 10.8% five-year OS, novel therapies are desperately needed.
Open AccessBRCA-Mutated Pancreatic Cancer: From Discovery to Novel Treatment Paradigms
The discovery of BRCA1 and BRCA2 in the 1990s revolutionized the way we research and treat breast, ovarian, and pancreatic cancers. In the case of pancreatic cancers, germline mutations occur in about 10–20% of patients, with mutations in BRCA1 and BRCA2 being the most common. BRCA genes are critical in DNA repair pathways, particularly in homologous recombination, which has a serious impact on genomic stability and can contribute to cancerous cell proliferation. However, BRCA1 also plays a fundamental role in cell cycle checkpoint control, ubiquitination, control of gene expression, and chromatin remodeling, while BRCA2 also plays a role in transcription and immune system response. Therefore, mutations in these genes lead to multiple defects in cells that may be utilized when treating cancer. BRCA mutations seem to confer a prognostic benefit with an improved overall survival due to differing underlying biology. These mutations also appear to be a predictive marker, with patients showing increased sensitivity to certain treatments, such as platinum chemotherapy and PARP inhibitors. Olaparib is currently indicated for maintenance therapy in metastatic PDAC after induction with platinum-based chemotherapy. Resistance has been found to these therapies, and with a 10.8% five-year OS, novel therapies are desperately needed.